vida: extract claims from 2026-04-23-itif-glp1-transformative-potential-2025

- Source: inbox/queue/2026-04-23-itif-glp1-transformative-potential-2025.md
- Domain: health
- Claims: 0, Entities: 1
- Enrichments: 3
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>

domains/health/federal-budget-scoring-methodology-systematically-undervalues-preventive-interventions-because-10-year-window-excludes-long-term-savings.md

@@ -1,15 +1,14 @@
 ---
 type: claim
 domain: health
-secondary_domains: [internet-finance, grand-strategy]
+description: CBO and ASPE diverge by $35.7B on GLP-1 Medicare coverage because budget scoring rules structurally discount prevention economics
-description: "CBO and ASPE diverge by $35.7B on GLP-1 Medicare coverage because budget scoring rules structurally discount prevention economics"
 confidence: likely
-source: "ASPE Medicare Coverage of Anti-Obesity Medications analysis (2024-11-01), CBO scoring methodology"
+source: ASPE Medicare Coverage of Anti-Obesity Medications analysis (2024-11-01), CBO scoring methodology
 created: 2026-03-11
-related_claims:
+secondary_domains: ["internet-finance", "grand-strategy"]
-  - divergence-prevention-first-cost-reduction-vs-cost-redistribution
+related_claims: ["divergence-prevention-first-cost-reduction-vs-cost-redistribution"]
-sourced_from:
+sourced_from: ["inbox/archive/health/2024-11-01-aspe-medicare-anti-obesity-medication-coverage.md"]
-- inbox/archive/health/2024-11-01-aspe-medicare-anti-obesity-medication-coverage.md
+related: ["federal-budget-scoring-methodology-systematically-undervalues-preventive-interventions-because-10-year-window-excludes-long-term-savings", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035", "medicaid-glp1-coverage-reversing-through-state-budget-pressure"]
 ---
 
 # Federal budget scoring methodology systematically undervalues preventive interventions because the 10-year scoring window and conservative uptake assumptions exclude long-term downstream savings
@@ -83,3 +82,9 @@ Topics:
 - domains/health/_map
 - core/mechanisms/_map
 - foundations/teleological-economics/_map
+
+## Extending Evidence
+
+**Source:** ITIF August 2025 policy recommendations
+
+ITIF explicitly advocates for 'dynamic scoring' in CBO modeling for GLP-1s, arguing that current static scoring underestimates economic benefits by not accounting for downstream cost reductions. They project 0.4% GDP increase (hundreds of billions in added output) if GLP-1 adoption expands at scale, including reduced healthcare spending, increased workforce productivity, and reduced disability—all benefits excluded from traditional 10-year budget windows.

domains/health/glp-1-access-structure-inverts-need-creating-equity-paradox.md

@@ -53,3 +53,10 @@ KFF national poll finds only 23% of obese/overweight adults currently taking GLP
 **Source:** ICER White Paper April 2025
 
 ICER's white paper explicitly focuses on 'payer sustainability strategies' rather than access expansion, and was criticized by the National Pharmaceutical Council for 'prioritizing payers over patients.' This institutional framing reveals that even rigorous health economics organizations are working on how to contain access, not expand it, because the cost trajectory threatens plan solvency.
+
+
+## Supporting Evidence
+
+**Source:** ITIF August 2025, cross-referenced with ICER/KFF data
+
+ITIF's 74 million eligible obesity treatment population figure provides the denominator for the 23% access rate documented in KFF polling. The contrast between ITIF's expansive potential framing (133M users, 0.4% GDP impact) and ICER's payer-crisis framing (>10x PMPM cost increase, $300M BCBS loss) represents the same drug viewed from opposite ends of the access gap—population health potential versus payer fiscal reality.

entities/health/information-technology-and-innovation-foundation.md

@@ -0,0 +1,24 @@
+# Information Technology and Innovation Foundation (ITIF)
+
+**Type:** Policy research organization  
+**Focus:** Pro-innovation technology policy advocacy  
+**Relevance:** GLP-1 access and economic impact analysis
+
+## Overview
+
+ITIF is a pro-innovation, pro-technology policy organization that produces research and advocacy on technology policy issues. In healthcare, they focus on access expansion and economic impact modeling for transformative therapeutics.
+
+## Timeline
+
+- **2025-08-18** — Published "A Shot at a Healthier Future: The Transformative Potential of GLP-1s" estimating 74M Americans eligible for GLP-1 obesity treatment and projecting 0.4% GDP increase if adoption expands at scale
+
+## Position
+
+ITIF advocates for:
+- Federal coverage expansion (Medicare and Medicaid) for GLP-1s
+- Dynamic scoring in CBO estimates to capture GDP/productivity gains
+- Continued basic research funding for GLP-1 mechanisms and new indications
+
+## Context
+
+ITIF reports should be read as advocacy for innovation adoption and access expansion, not neutral analysis. Their economic projections are modeling exercises rather than observed data, but they usefully quantify the scale of potential societal impact if structural access barriers were overcome.

inbox/archive/health/2026-04-23-itif-glp1-transformative-potential-2025.md

@@ -7,9 +7,12 @@ date: 2025-08-18
 domain: health
 secondary_domains: []
 format: policy report
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-04-23
 priority: medium
 tags: [glp-1, policy, access, GDP, economic-impact, obesity, coverage, workforce, population-health]
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content